U.S. FDA delays risk ceding cancer-cure lead to China, seniors could suffer

The piece contends that the United States' long-standing dominance in medical innovation is under threat from an FDA that extends drug approvals for years after safety is established. China is rapidly accelerating its biotech pipeline, moving from discovery to human trials roughly 70% faster than any other country, positioning itself to lead the next generation of cancer cures. The author cites that cutting just one year from review times could generate $10.2 trillion in economic value and that eliminating cancer mortality could add $186 trillion over 35 years.

He urges the adoption of modern tools such as artificial intelligence and adaptive clinical trial designs to streamline effectiveness assessments while preserving rigorous safety oversight. The argument emphasizes that seniors, who have benefited from past breakthroughs, cannot afford to lose this leadership. Saulius “Saul” Anuzis, president of the 60 Plus Association, frames the issue as both a health and economic priority for the nation.